MetaCap

Aktis Oncology (AKTS) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aktis Oncology is the larger company by market cap ($901.1 million vs $816.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTS-27.90%PHAR-38.32%
+49%-4%-56%
Jan 9, 20261 yearNov 20, 2026
AKTS-27.90%PHAR-38.32%
+46%-4%-55%
Jan 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTS versus PHAR key metrics
MetricAKTSPHAR
Share price$16.15$11.54
Market cap$901.14M$816.78M
1-day change-1.52%-5.10%
YTD return—-34.69%
1-year return—-29.03%
5-year return—+39.04%
P/E ratio (TTM)—36.06
Forward P/E—64.11
EPS (TTM)$-1.80$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$376.13M
Revenue growth (YoY)—+26.56%
Net income (latest FY)—$2.85M
Gross margin—87.90%
Operating margin—6.87%
Net margin—0.76%
52-week high$34.19$21.34
52-week low$13.96$9.11
Distance from 52-week high-52.76%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+122.17%+209.36%
Average volume408.46K21.33K
Shares outstanding53.93M70.78M
Employees79407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aktis Oncology

AKTS stock →

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

AKTS vs PHAR FAQ

Which is bigger, Aktis Oncology or Pharming Group N.V.?

Aktis Oncology (AKTS) is larger, with a market capitalization of $901.14M compared with $816.78M for Pharming Group N.V. (PHAR).

Are Aktis Oncology and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons